BridgeBio Pharma, Inc.
BBIO$14.35B
Large CapNASDAQBiotechnology🇺🇸North America725 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BBIO News
Catalyst Timeline
0 upcoming, 2 past
No catalysts found.
Drug Pipeline
Acoramidis
Amyloidosis
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
AG10
Familial ATTR-CM (ATTRm-CM, or FAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis | Phase 3 | Amyloidosis | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
AG10 | Phase 2 | Familial ATTR-CM (ATTRm-CM, or FAC) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply